Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Precigen Inc

PGEN ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$6.10

▼ -6.01%

Market Cap $2.18B · Vol 2.14M

Key Metrics

P/E Ratio

N/A

FWD: 12.09

Market Cap

$2.18B

Mid Cap

Div Yield

N/A

EPS Growth

+116.06%

YoY

RSI (14)

60.43

Momentum

Beta

0.99

vs Market

52W High

$7.31

16.55% below

52W Low

$2.51

143.03% above

Volume

2.14M

Avg 1.40M

P/B

70.74

Price-to-book

ROE

-1,446.02%

Return on equity

Free Float

87.33%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Precigen Inc (PGEN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PGEN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-15.63%

+19.14%

+32.61%

+23.73%

YTD

+45.93%

+229.73%

+298.69%

-0.65%

Financials & Valuation

TTM · Annual

Total Revenue	$9.68M
Net Income	$-250,642,000.00
Revenue Growth (YoY)	+6,322.66%
Gross Margin	50.20%
Operating Margin	-1,100.78%
Net Profit Margin	-2,588.21%
ROE	-1,446.02%
ROA · ROIC	-166.66% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	12.09
PEG Ratio	N/A
P/S	135.09
P/B	70.74
P/FCF	N/A
EPS Growth	+116.06%
Outstanding Shares	358.04M

Technical Indicators

50-Day SMA	$5.45
200-Day SMA	$4.42
RSI (14)	60.43
Beta	0.99
52-Week High	$7.31
52-Week Low	$2.51

Volume Today	2.14M
Avg Daily Volume (30D)	1.40M
Relative Volume	1.54x
Volatility (10D)	63.26
Volatility (30D)	58.46
Free Float	87.33%

Analyst Consensus

BUY

Current Price $6.10

Mean Target $14.50

52W Low$2.51 52W High$7.31

Current

Target

$2.51 $7.31

Current Analyst target

+137.70% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SSB3T5

ISINUS74017N1054

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.